Company / SG&A Expense
Cocrystal Pharma, Inc. SG&A Expense History
FY2012-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$5.4M
FY2021
5-year range
$2.1M / $5.4M
FY2017-FY2021
Trend
+11.6%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 3 consecutive years, from $2M in FY2012 to $5M in FY2021.
Based on SEC 10-K filings.
$5M in FY2021.
Increased from $4M to $5M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Cocrystal Pharma, Inc.'s sg&a expense has grown for 3 consecutive years.
- In FY2021, sg&a expense increased 11.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score 14.87 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $5.4M | +11.6% |
| FY2020 | $4.9M | +11.7% |
| FY2019 | $4.4M | +110.8% |
| FY2012 | $2.1M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026